Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.45 USD
Change Today +0.22 / 0.64%
Volume 449.3K
SPNC On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Open
$33.92
Previous Close
$34.23
Day High
$34.82
Day Low
$33.32
52 Week High
03/18/15 - $37.04
52 Week Low
05/7/14 - $20.07
Market Cap
1.5B
Average Volume 10 Days
350.1K
EPS TTM
$-0.46
Shares Outstanding
42.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $596.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.2K
Chief Operating Officer
Total Annual Compensation: $265.6K
Senior Vice President and General Counsel
Total Annual Compensation: $238.9K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $176.0K
Compensation as of Fiscal Year 2013.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Announces Management Changes

The Spectranetics Corporation announced that Guy Childs, Chief Financial Officer, has announced his plan to transition from his current role. Mr. Childs will continue to serve as the Company's Chief Financial Officer until his replacement has been hired. Following the transition, Mr. Childs will continue to serve as an officer of the company in a Vice President role that will include treasury, investor relations and financial planning.

The Spectranetics Corporation Appoints Todd C. Schermerhorn as Director

The Spectranetics Corporation appointed Todd C. Schermerhorn to the Board, effective March 12, 2015. Mr. Schermerhorn served as Senior Vice President and Chief Financial Officer of C.R. Bard Inc. from 2003 until his retirement in August 2012. Mr. Schermerhorn was promoted to Vice President and Group Controller for Bard's Global Cardiology Unit. He was promoted to Vice President and Treasurer in 1998. Mr. Schermerhorn serves on the board of directors of Thoratec Corporation.

The Spectranetics Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

The Spectranetics Corporation announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenue was $62,959,000 against $41,920,000 a year ago. Operating loss was $13,770,000 against income of $1,771,000 a year ago. Loss before taxes was $15,634,000 against income of $1,768,000 a year ago. Net loss was $14,731,000 or $0.35 per basic and diluted share against income of $883,000 or $0.02 per basic and diluted share a year ago. Non-GAAP net loss was $1,742,000 or $0.04 per share compared to income of $682,000 or $0.02 per share a year ago. Adjusted EBITDA was $3,249,000 against $3,984,000 a year ago. For the year, revenue was $204,914,000 against $158,811,000 a year ago. Operating loss was $36,950,000 against income of $394,000 a year ago. Loss before taxes was $41,223,000 against income of $410,000 a year ago. Net loss was $40,901,000 or $0.98 per basic and diluted share against $370,000 or $0.01 per basic and diluted share a year ago. Non-GAAP net loss was $11,326,000 or $0.27 per share compared to income of $723,000 or $0.02 per share a year ago. Adjusted EBITDA was $4,158,000 against $11,205,000 a year ago. For the fiscal year 2015, the company expects net loss, GAAP to be in the range of $62.0 to $58.0 million, non-GAAP net loss to be in the range of $35.9 million to $31.9 million, net loss per share, GAAP to be in the range of $1.46 to $1.36, non-GAAP net loss per share to be in the range of $0.84 to $0.75. The company to project revenue in the range of $258 million to $265 million, an increase of 26% to 29% over 2014. The company estimates the negative impact of a weakening euro at approximately $3 million. Projected sales from the Stellarex DCB products are anticipated to largely offset the foreign currency impact in 2015. Gross margin is expected to be in the range of 74.5% to 75.0%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $34.45 USD +0.22

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.56 USD -0.12
AtriCure Inc $21.06 USD -0.82
Cardiovascular Systems Inc $37.58 USD -0.21
CryoLife Inc $9.98 USD -0.06
Endologix Inc $16.35 USD -0.15
View Industry Companies
 

Industry Analysis

SPNC

Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit www.spectranetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.